Related Experiment Video
Updated: Jun 3, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Intermittent hormonal therapy for prostate cancer
1Grupo Português Genito-Urinário, Lisbon, Portugal. calais@seug-gpgu.com
Current Opinion in Urology
|March 24, 2011
Summary
Intermittent hormonal therapy (IHT) offers a promising approach for prostate cancer management. This strategy aims to reduce side effects and potentially delay disease progression, improving patient quality of life.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer treatment often involves continuous androgen deprivation therapy.
- Continuous therapy can lead to significant side effects and reduced quality of life.
Purpose of the Study:
- To evaluate the efficacy and benefits of intermittent hormonal therapy (IHT) for prostate cancer.
- To explore IHT's potential in minimizing treatment-related side effects and improving patient quality of life.
- To assess IHT's role in delaying progression to castration-resistant prostate cancer.
Main Methods:
- Review of preclinical evidence and clinical trial data (Phase II and III) on IHT.
- Analysis of studies focusing on time to androgen independence and treatment complications.
Main Results:
- Preclinical data suggest IHT may delay androgen independence.
- Phase II and III studies show optimistic results for IHT.
- IHT demonstrates potential for cost reduction and fewer complications compared to continuous therapy.
Conclusions:
- Intermittent hormonal therapy is emerging as a valuable treatment strategy for prostate cancer.
- IHT is particularly beneficial for men with locally advanced disease.
- The adoption of IHT is increasing globally due to its advantages.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...